Synonyms: Example 1 [WO2020252151A1] [1]
Compound class:
Synthetic organic
Comment: We obtained the chemical structure for tilpisertib fosmecarbil from the WHO's proposed INN list 127 (21 July 2022). In this document it was described as a serine/ threonine kinase inhibitor and anti-inflammatory agent. The chemical structure is amongst those that are claimed as Cot (a.k.a. MAP3K8/TPL2) modulators in patent WO2020252151A1 [1]. Inhibition of Cot (which is an upstream regulator in the MEK-ERK pathway) is expected to reduce production and signalling of TNFα, for application in auto-inflammatory diseases. Gilead's development pipeline contains a TPL2 inhibitor, GS-5290, that is in phase 1 for inflammatory bowel disease. Tilpisertib fosmecarbil is likely a follow-up to the parent molecule tilpisertib (formerly GS-4875) that was tested in ulcerative colitis trial NCT04130919.
|
|
Classification | |
Compound class | Synthetic organic |
IUPAC Name |
phosphonooxymethyl N-[(S)-[1-(1-bicyclo[1.1.1]pentanyl)triazol-4-yl]-(2-methyl-1-oxoisoquinolin-5-yl)methyl]-N-[8-chloro-3-cyano-4-(2,2-dimethylpropylamino)quinolin-6-yl]carbamate |
International Nonproprietary Names | |
INN number | INN |
12278 | tilpisertib fosmecarbil |
Synonyms | |
Example 1 [WO2020252151A1] [1] |
Database Links | |
CAS Registry No. | 2567459-64-5 (source: WHO INN record) |
GtoPdb PubChem SID | 472319203 |
PubChem CID | 155407072 |
Search Google for chemical match using the InChIKey | FPQIBCPWXJSFOQ-ILNPBIMBSA-N |
Search Google for chemicals with the same backbone | FPQIBCPWXJSFOQ |
Search PubMed clinical trials | tilpisertib fosmecarbil |
Search PubMed titles | tilpisertib fosmecarbil |
Search PubMed titles/abstracts | tilpisertib fosmecarbil |
UniChem Compound Search for chemical match using the InChIKey | FPQIBCPWXJSFOQ-ILNPBIMBSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | FPQIBCPWXJSFOQ-ILNPBIMBSA-N |